DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

a I-SPY 2 TRIAL design schematic. Only patients with HER2？ disease were eligible for randomization to the VC arm. b Consort diagram for the VC arm and HER2？ concurrent controls, showing data availability for biomarker analysi